Literature DB >> 8236145

Platelet activating properties of murine monoclonal antibodies to beta 2-glycoprotein I.

J Arvieux1, B Roussel, P Pouzol, M G Colomb.   

Abstract

Previously developed murine monoclonal antibodies (MAbs) to human beta 2-glycoprotein I (beta 2 GPI), a plasma protein required for the binding of anti-phospholipid antibodies, were studied for anti-platelet reactivity and influence on platelet function. The six MAbs (IgG1 isotype) tested interacted with both intact and fixed platelets in a beta 2 GPI-dependent manner. Carbamylated beta 2 GPI was still recognized by MAbs but was unable to mediate platelet-antibody binding. MAbs induced aggregation and secretion responses of platelets in platelet-rich plasma (PRP) and whole blood, provided subthreshold concentrations of weak agonists (i.e. ADP or adrenaline) were added. When aggregation in PRP was evaluated by a counting technique instead of turbidometrically, the sole addition of MAbs led to a rapid fall in single platelets. Triggering gel-filtered platelets with MAbs together with beta 2 GPI, but not its carbamylated form, led to platelet activation after a lag time, as monitored by aggregometry, measurements of ATP and beta-thromboglobulin secretion and calcium mobilization. F(ab')2 fragments of one of the MAbs failed to activate platelets but inhibited the responses to the whole antibody. This process thus depends on MAbs binding to platelets through both Fab and Fc domains, as confirmed by the suppression of platelet responses upon pretreatment with the anti-Fc gamma RII MAb IV.3. Aggregation and secretion induced by MAbs plus beta 2 GPI did not require exogenous fibrinogen and were variably inhibited in the presence of acetyl salicylic acid, apyrase or Ca2+, depending on the concentrations used for the two proteins.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8236145

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Relationship of microparticles with beta 2-glycoprotein I and P-selectin positivity to anticardiolipin antibodies in immune thrombocytopenic purpura.

Authors:  S Nomura; M Yanabu; T Miyake; Y Miyazaki; H Kido; H Kagawa; S Fukuhara; Y Komiyama; E Matsuura; T Koike
Journal:  Ann Hematol       Date:  1995-01       Impact factor: 3.673

Review 2.  Anti-beta 2-glycoprotein I antibodies.

Authors:  J Arvieux; J C Bensa; B Roussel; M G Colomb
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 3.  Anti-beta 2-glycoprotein I antibodies and thrombosis.

Authors:  J P Viard; Z Amoura; J F Bach
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

4.  Anti-vWf antibodies induce GPIbalpha and FcgammaRII mediated platelet aggregation only at low shear forces.

Authors:  M F Hoylaerts; A Viaene; C Thys; H Deckmyn; J Vermylen
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

5.  Both kinetic data and epitope mapping provide clues for understanding the anti-coagulant effect of five murine monoclonal antibodies to human beta2-glycoprotein I.

Authors:  V Regnault; J Arvieux; L Vallar; T Lecompte
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

6.  IgG2 subclass restriction of anti-beta 2 glycoprotein 1 antibodies in autoimmune patients.

Authors:  J Arvieux; B Roussel; D Ponard; M G Colomb
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

Review 7.  Morphology of vascular, renal, and heart lesions in the antiphospholipid syndrome: relationship to pathogenesis.

Authors:  M C Amigo; R García-Torres
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.